Clinical trials: COPD Patients
Chronic Obstructive Pulmonary Disease
A Phase 2 Study of MP-376 to Prevent Acute Exacerbations in Chronic Obstructive Pulmonary Disease (COPD) Patients
Patients with Chronic Obstructive Pulmonary Disease (COPD) suffer from frequent and recurrent acute exacerbations (AECB) which are associated with enormous healthcare expenditures and significant morbidity, specifically an…
- Trial name
- NCT00739648
- Testing
- MP-376
- Where
- 39 sites in United States
- Volunteers
- 322 people
- Sponsor
- Amgen
Chronic Obstructive Pulmonary Disease
Effect of Indacaterol on Inspiratory Capacity (IC)
This study is being conducted to assess the effect of indacaterol (150 μg o.d.) on inspiratory capacity (IC), using placebo and open label tiotropium (18 μg o.d.) as comparators in patients with moderate chronic obstructive…
- Trial name
- NCT01012765
- Testing
- Indacaterol, Tiotropium
- Where
- 21 sites in Germany
- Volunteers
- 173 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease
Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of SAR440340 (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)
Primary Objective: To investigate effects of SAR440340 (anti-interleukin-33 [IL-33] monoclonal antibody [mAb]) compared with placebo, on the annualized rate of moderate-to-severe acute exacerbations of COPD (AECOPD) over up to 52…
- Trial name
- NCT03546907
- Testing
- SAR440340, Any Inhaled Corticosteroids as prescribed by treating physician as standard of care, Any Long Acting Beta Agonist as prescribed by treating physician as standard of care
- Where
- 83 sites in United States, Argentina and 8 more
- Volunteers
- 343 people
- Sponsor
- Sanofi
Chronic Obstructive Pulmonary Disease
Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Chronic Obstructive Pulmonary Disease (COPD)
This is a Phase 3B, 12-week, multicenter, open-label study to evaluate the relationship between as-needed usage of albuterol eMDPI and Clinical Exacerbation-Chronic Obstructive Pulmonary Disease (CE-COPD) in adult participants at…
- Trial name
- NCT03256695
- Testing
- Albuterol sulfate (ABS)
- Where
- 40 sites in United States
- Volunteers
- 405 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Chronic Obstructive Pulmonary Disease (COPD)
Efficacy and Tolerability of Symbicort as an add-on Treatment to Spiriva Compare With Spiriva Alone in Patients With Severe Chronic Obstructive Pulmonary Disease (COPD)
This is a multicentre study with a randomised, parallel group, open-label, 3-month phase IV design to assess the efficacy and tolerability of Symbicort as an add-on treatment to Spiriva compare with Spiriva alone in patients with…
- Trial name
- SECURE 1 (NCT01397890)
- Testing
- Budesonide/formoterol (Symbicort® Turbuhaler®), Tiotropium (SpirivaTM)
- Where
- 31 sites in China, Hong Kong and 3 more
- Volunteers
- 793 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive (COPD)
Preference on the Feedback Mechanisms of Dose Delivery Confirmation With the Breezhaler® Device Compared to the Ellipta® Device in Patients With Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to compare in COPD patients naïve to DPIs, the perception of the Breezhaler® and Ellipta® devices' feedback mechanisms evaluated using a preference questionnaire.
- Trial name
- Advantage (NCT02551224)
- Testing
- Patient preference questionnaire
- Where
- 10 sites in Argentina
- Volunteers
- 100 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Disease, Chronic Obstructive, Major Depression
Treatment of Depressed Chronic Obstructive Pulmonary Disease Patients
Approximately 20% of patients with chronic obstructive pulmonary disease (COPD) have major depression, a condition that contributes to suffering but also to poor treatment adherence leading to increased disability and morbidity.
- Trial name
- NCT00151372
- Testing
- Treatment Adherence Intervention, Enhanced Care
- Where
- 3 sites in United States
- Volunteers
- 141 people
- Sponsor
- Weill Medical College of Cornell University
Pulmonary Disease, Chronic Obstructive
Cardiovascular Events in Chronic Obstructive Pulmonary Disease Patients Initiating Olodaterol or Other Long-acting beta2 Agonists
Examine the risk of cardiovascular events (cardiac arrhythmia or myocardial ischemia) or all-cause mortality in Chronic Obstructive Pulmonary Disease (COPD) patients who are new users of Olodaterol or other LABAs available for…
- Trial name
- NCT03405363
- Where
- Denmark
- Volunteers
- 65,406 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Effects of N-acetylcysteine on Cardiorespiratory Control in COPD Patients With Mild-to-moderate Airflow Obstruction
The main purpose of this study is to determine whether pharmacological treatment with N-acetylcysteine improves central and peripheral cardiorespiratory control and physical capacity in COPD patients with mild-to-moderate airflow…
- Trial name
- NCT02579772
- Testing
- N-acetylcysteine
- Volunteers
- 13 people
- Sponsor
- Queen's University
Pulmonary Disease, Chronic Obstructive
The ENERGITO® 2 Study Compares 2 Inhaled Medicines for Chronic Obstructive Pulmonary Disease (COPD). One Medicine is a Combination of Tiotropium and Olodaterol (Stiolto®) Taken Using the Respimat® Inhaler and the Other Medicine is a Combination of Fluticasone and Salmeterol Taken Using the Diskus
The primary objective of the trial is to show superiority in lung function of once daily (2 inhalations) treatment with orally inhaled tiotropium+olodaterol fixed dose combination to twice daily (one inhalation) treatment with…
- Trial name
- NCT03240575
- Testing
- Tiotropium, Olodaterol, Fluticasone propionate
- Where
- 45 sites in United States
- Volunteers
- 302 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
12 / 48 Week Pivotal PFT vs PBO in COPD I
This primary objective of this study is to compare two doses of BI 1744 CL inhalation solution delivered by the Respimat® inhaler once daily to placebo in patients with chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT00782210
- Testing
- Olodaterol (BI1744)
- Where
- 54 sites in United States, Australia and 4 more
- Volunteers
- 625 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease
Efficacy and Safety Study of QVA149 in COPD Patients
The purpose of this study is to demonstrate that the efficacy of the combination product QVA149 is similar to the efficacy of the combination product umeclidinium/vilanterol on a pre-specified endpoint of FEV1 AUC0-24h while…
- Trial name
- NCT02487446
- Testing
- QVA149, Umeclidinium/vilanterol
- Where
- 58 sites in United States
- Volunteers
- 357 people
- Sponsor
- Novartis Pharmaceuticals
COPD
Peak Inspiratory Flow Rates in Patients With COPD
Recent studies have reported that some Chronic Obstructive Pulmonary Disease (COPD) patients may have a suboptimal ability to generate a sufficient inspiratory effort to achieve adequate lung delivery of inhaled medications…
- Trial name
- NCT04168775
- Testing
- Home PIFR monitoring with InCheck Dial
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- University of North Carolina, Chapel Hill
COPD Asthma
Pulmonary Specialist-Health Coach Consult Model Study
The Pulmonary Specialist-Health Coach Consultation (PuSHCon) study examines the implementation of health coach-assisted consultations to improve access to specialist care and implementation of specialist recommendations for…
- Trial name
- PuSHCon (NCT03695276)
- Testing
- PushCon Model, Usual care
- Where
- 11 sites in United States
- Volunteers
- 328 people
- Sponsor
- University of California, San Francisco
Pulmonary Disease, Chronic Obstructive
A Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent Inhalation Aerosol in COPD Patients.
The objective of this study is to evaluate the efficacy and safety of 12 weeks treatment with tiotropium HandiHaler 18 micrograms (mcg) daily compared to Combivent Metered Dose Inhaler (MDI) Chlorofluorocarbon Inhalation Aerosol…
- Trial name
- NCT00359788
- Testing
- tiotropium, Combivent (Ipratropium/Albuterol)
- Where
- 31 sites in United States
- Volunteers
- 349 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease (COPD)
Effect of Rosuvastatin Therapy in Patients With Stable Chronic Obstructive Pulmonary Disease
The purpose of this study is to investigate whether rosuvastatin improves measures of endothelial function, decreases measures of inflammation, and improves pulmonary function in patients with stable chronic obstructive pulmonary…
- Trial name
- RODEO (NCT00929734)
- Testing
- Rosuvastatin
- Where
- Norway
- Volunteers
- 99 people
- Sponsor
- University Hospital, Akershus
Chronic Obstructive Pulmonary Disease
Evaluating Forced Oscillation Technique (FOT) in Abolishing Flow Limitation
To validate the capability of the Respironics Synchrony ventilator to properly detect Expiratory Flow Limitation (EFL) as compared to the gold standard method of detecting EFL via the Mead and Wittenberger technique.
- Trial name
- NCT01151618
- Testing
- Respironics Synchrony ventilator (Non Invasive Ventilation)
- Where
- United Kingdom
- Volunteers
- 22 people
- Sponsor
- Philips Respironics
Pulmonary Disease, Chronic Obstructive
Effect of Tiotropium + Olodaterol on Breathlessness in COPD Patients
The primary objective of the present study is to evaluate the effect of tiotropium + olodaterol fixed dose combination (FDC) compared to tiotropium monotherapy on the intensity of breathlessness during the 3min constant speed…
- Trial name
- NCT02853123
- Testing
- Tiotropium, Olodaterol
- Where
- 13 sites in Belgium, Canada and 2 more
- Volunteers
- 106 people
- Sponsor
- Boehringer Ingelheim
Patients With Moderate-to-severe COPD With Destroyed Lung by Tuberculosis
Indacaterol EfectIveness In COPD Patients With Tuberculosis History
This clinical study will assess efficacy and safety of indacaterol (150㎍ o.d.) in patients with Chronic Obstructive Pulmonary Disease (COPD) with destroyed lung by tuberculosis.
- Trial name
- INFINITY (NCT01778062)
- Testing
- Indacaterol, Control
- Where
- 13 sites in South Korea
- Volunteers
- 136 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease
Efficacy, Tolerability and Safety of NVA237 in Patients With Chronic Obstructive Pulmonary Disease
This study will assess the efficacy, tolerability and safety of NVA237 compared to tiotropium when added on to fluticasone/salmeterol in patients with chronic obstructive pulmonary disease.
- Trial name
- NCT01513460
- Testing
- NVA237 50µg once daily, Tiotropium 18µg once daily, Flu/Sal
- Where
- 71 sites in Australia, New Zealand
- Volunteers
- 773 people
- Sponsor
- Novartis Pharmaceuticals